OBJECT DRUGS
Chemotherapy agents (CYP3A4 Substrates):
- Abiraterone (Zytiga)
- Anastrozole (Arimidex)
- Aprepitant (Emend)
- Bexarotene (Targretin)
- Bortezomib (Velcade)
- Brentuximab (Adcetris)
- Cabazitaxel (Jevtana)
- Cyclophosphamide (Cytoxan)
- Docetaxel (Taxotere)
- Doxorubicin (Adriamycin)
- Enzalutamide (Xtandi)
- Etoposide (Vepesid)
- Exemestane (Aromasin)
- Ifosfamide (Ifex)
- Ixabepilone (Ixempra)
- Ixazomib (Ninlaro)
- Letrozole (Femara)
- Paclitaxel (Taxol)
- Panobinostat (Farydak)
- Sonidegib (Odomzo)
- Teniposide (Vumon)
- Toremifene (Fareston)
- Trabectedin (Yondelis)
- Venetoclax (Venclexta)
PRECIPITANT DRUGS
Enzyme Inducers:
- Barbiturates
- Bosentan (Tracleer)
- Carbamazepine (Tegretol, etc.)
- Dabrafenib (Tafinlar)
- Efavirenz (Sustiva)
- Etravirine (Intelence)
- Lumacaftor (Orkambi)
- Nevirapine (Viramune, etc.)
- Oxcarbazepine (Trileptal, etc.)
- Phenytoin (Dilantin, etc.)
- Primidone (Mysoline)
- Rifabutin (Mycobutin)
- Rifampin (Rifadin, etc.)
- Rifapentine (Priftin)
- St. John's wort
Comment:
Although data are limited, these enzyme inducers may decrease the plasma levels of chemotherapy agents. Reduction in the expected antineoplastic activity or resistance may occur.
Class 2: Use Only If Benefit Felt to Outweigh Risk
- Monitor: Monitor for altered antineoplastic response if the CYP3A4 inducer is initiated, discontinued, or changed in dosage.